Cargando…
ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb),...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370427/ http://dx.doi.org/10.1093/abt/tbad014.017 |
_version_ | 1785077931601559552 |
---|---|
author | Jiang, Kai Li, Huishuai Tang, Chuanlong Zhang, Dawei Zhang, Xuejian Zhang, Ying Zhao, Zhengyang Zhou, Jun Lu, Mengjie Xiao, Yongsheng Feng, Zhumei Wu, Jiansheng |
author_facet | Jiang, Kai Li, Huishuai Tang, Chuanlong Zhang, Dawei Zhang, Xuejian Zhang, Ying Zhao, Zhengyang Zhou, Jun Lu, Mengjie Xiao, Yongsheng Feng, Zhumei Wu, Jiansheng |
author_sort | Jiang, Kai |
collection | PubMed |
description | Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb), bispecific antibodies (bsAbs) as well as other Fc fusion proteins. High-throughput production (HTP) of various proteins with high quality in very short time is a big challenge in industry. Here we present how WuXi Biologics has created a powerful ultra HTP protein production platform (termed as “Ultra 96”) that can automatically produce proteins within 3 weeks with one step purification at 1~3mL expression scale by using 96 and 24 well DWP. High titer of expression, high quality of products, short timeline as well as low cost make “Ultra 96” a robust platform which can empower our clients and dramatically accelerate their early stage drug discovery projects. |
format | Online Article Text |
id | pubmed-10370427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103704272023-07-27 ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES Jiang, Kai Li, Huishuai Tang, Chuanlong Zhang, Dawei Zhang, Xuejian Zhang, Ying Zhao, Zhengyang Zhou, Jun Lu, Mengjie Xiao, Yongsheng Feng, Zhumei Wu, Jiansheng Antib Ther Abstract Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb), bispecific antibodies (bsAbs) as well as other Fc fusion proteins. High-throughput production (HTP) of various proteins with high quality in very short time is a big challenge in industry. Here we present how WuXi Biologics has created a powerful ultra HTP protein production platform (termed as “Ultra 96”) that can automatically produce proteins within 3 weeks with one step purification at 1~3mL expression scale by using 96 and 24 well DWP. High titer of expression, high quality of products, short timeline as well as low cost make “Ultra 96” a robust platform which can empower our clients and dramatically accelerate their early stage drug discovery projects. Oxford University Press 2023-07-24 /pmc/articles/PMC10370427/ http://dx.doi.org/10.1093/abt/tbad014.017 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstract Jiang, Kai Li, Huishuai Tang, Chuanlong Zhang, Dawei Zhang, Xuejian Zhang, Ying Zhao, Zhengyang Zhou, Jun Lu, Mengjie Xiao, Yongsheng Feng, Zhumei Wu, Jiansheng ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title | ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title_full | ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title_fullStr | ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title_full_unstemmed | ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title_short | ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES |
title_sort | establishment of an ultra high-throughput protein production platform (ultra 96) for early stage in vitro studies |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370427/ http://dx.doi.org/10.1093/abt/tbad014.017 |
work_keys_str_mv | AT jiangkai establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT lihuishuai establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT tangchuanlong establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT zhangdawei establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT zhangxuejian establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT zhangying establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT zhaozhengyang establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT zhoujun establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT lumengjie establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT xiaoyongsheng establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT fengzhumei establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies AT wujiansheng establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies |